BIOMÉRIEUX : Berenberg upgrades its recommendation to 'buy
While Berenberg believes that the lower-than-expected 2024 full-year forecasts communicated at the time of the 2023 earnings release do not come as a real surprise, the analyst points out that the excellent performance of the Spotfire multiplex PCR platform is far more surprising.
In this sense, Berenberg considers that the healthcare group's medium-term prospects are currently underestimated by the market, as the return to growth in respiratory testing is accompanied, in his opinion, by successful product launches and good performances in non-respiratory analysis.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Go to the original article.
Contact us to request a correction